TARGET, NCT00589472: Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer |
|
|
| Completed | 2 | 19 | US | Bicalutamide, Casodex, Cosudex, ICI 176,334, ICI 176334, Goserelin Acetate, ZDX, Zoladex, Laboratory Biomarker Analysis, Leuprolide Acetate, A-43818, Abbott 43818, Abbott-43818, Carcinil, Depo-Eligard, Eligard, Enanton, Enantone, Enantone-Gyn, Ginecrin, LEUP, Leuplin, Leuprorelin Acetate, Lucrin, Lucrin Depot, Lupron, Lupron Depot, Lupron Depot-3 Month, Lupron Depot-4 Month, Lupron Depot-Ped, Procren, Procrin, Prostap, TAP-144, Trenantone, Uno-Enantone, Viadur, Therapeutic Conventional Surgery, Vorinostat, L-001079038, SAHA, Suberanilohydroxamic Acid, Suberoylanilide Hydroxamic Acid, Zolinza | National Cancer Institute (NCI) | Prostate Adenocarcinoma, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer | 06/10 | 06/10 | | |
